ASX Announcement17 January 2020PRIZMA CLINICAL TRIALS COMPLETED...

ASX Announcement17 January 2020PRIZMA CLINICAL TRIALS COMPLETED FORCHINA NMPA APPROVAL PROCESS

Prizma deviceclinical trials with208 patients completed across multiplehospitals in China
Major milestone in the China regulatory approval process -potentially unlocks large market entry
Trial results to be lodged with National Medical Products Administration in coming weeks
NMPAapproval will unlock GMedical’s China market entry